

References

- Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, co-morbidities and management in general practice 2000-2005. *Ann Rheum Dis* 2008; 67: 960-66.
- Chen SY, Chen CL, Shen ML and Kamatani NN. Trends in the manifestations of gout in Taiwan. *Rheumatology* 2003; 42(12):1529-33.
- Chaiamnuay P, Darmawan J, Muirden KD and Assawatanabodee P. Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. *J Rheumatol* 1998; 25(7): 1382-7.
- Chuang SY, Lee SC, Hsieh YT and Pan WH. Trends in hyperuricemia and gout prevalence: nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. *Asia Pac J Clin Nutr* 2011; 20 (2): 301-308.
- Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. *Cleve Clin J Med* 2008; 75(5):13-16.
- Fuldeore MJ, Riedel A, Zarotsky V, Pandya BJ, Dabbous O and Krishnan E. Chronic Kidney Disease in gout in a managed care setting. *BMC Nephrology* 2011; 12(36): 1-9.
- Harris CM, Lloyd DC and Lewis J. The prevalence and prophylaxis of gout in England. *J Clin Epidemiol* 1995; 48(9): 1153-58.
- Hyon C, Karen A, Elizabeth K, Walter W and Gary Cu. Purine-Rich Foods, Dairy and Protein Intake and the Risk of Gout in Men. *N Engl J Med* 2004; 350: 1093-1103.

- Kang DH and Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. *Semin Nephrol* 2005; 25(1): 43-9.
- Klemp P, Stansfield S, Castle B and Robertson M. Gout is on the increase in New Zealand. *Ann Rheum Dis* 1997; 56(1): 22-6.
- Kumar S and Gow P. A survey of indications, results and complications of surgery for tophaceous gout. *N Z Med J* 2002; 115(1158): 109-20.
- Liote F, Lancrenon S, Lanzf S, Guggenbuhl P, Lambert C, Saraux A, et al. GOSPEL: Prospective survey of gout in France. Part I: Design and patient characteristics (n= 1003). *Joint Bone Spine* 2012; 1-7.
- Locatelli F, Vecchio LD and Pozzoni P. The importance of early detection of chronic kidney disease. *Nephrol Dial Transplant* 2002; 17 Suppl 11: 2-7.
- McNeil, D. *Epidemiological Research Methods* (1996). New York: John Wiley and Sons Ltd; 1996.
- National Kidney Foundation-K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, Classification and stratification. *Am J Kidney Dis* 2002; 392(1): 261-6.
- Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R and Klauser B. Elevated Uric Acid Increases the Risk for Kidney Disease. *J Am Soc Nephrol* 2008; 19(12): 2407-13.
- Roddy E and Doherty M. Epidemiology of gout. *Arthritis Res Ther* 2010; 12(6): 223-234.
- Smith EU, Diaz-Torne C, Perez RF and March LM. Epidemiology of gout: an update. *Best Pract Res Clin Rheumatol* 2010; 24:811-27.

Tausche AK, Wunderlich C and Aringer M. Tophaceous gout and renal insufficiency:

a new solution for an old therapeutic dilemma. *Case Report Med.* 2011; 2011.

Wallace KL, Riedel AA, Joseph-Ridge N and Wortmann R. Increasing prevalence of

gout and hyperuricemia over 10 years among older adults in a managed care

population. *J Rheumatol* 2004; 31(8):1582-7.

Weaver L. Epidemiology of gout. *Cleve Clin J Med* 2008; 75: 9-12.